Skip to main content

Table 1 The clinical and histopathological characteristics of the included patients

From: Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer

Characteristics Number of patients (% of total)
Total ER positive ER negative P value
Enrolled patients 313 190 123  
Tumor size (mean), cm 2.17 2.03 2.40  
  <2 170 121(63.7%) 49(39.8%) <0.001
  2-5 138 65(34.2%) 73(59.3%)  
  ≥5 5 4(2.1%) 1(0.8%)
Nodal status     
  0 206 130(68.4%) 76(61.8%) 0.310
  1-3 81 44(23.2%) 37(30.1%)
  4-9 14 7(3.7%) 7(5.7%)
  ≥10 12 9(4.7%) 3(2.4%)
Nuclear grade     <0.001
  Grade 1 or 2 127 109(57.4%) 18(14.6%)
  Grade 3 175 76(40.0%) 99(80.5%)
  Unknown 11 5(2.6%) 6(4.9%)
Histologic grade     <0.001
  Grade 1 or 2 131 113(59.5%) 18(14.6%)
  Grade 3 153 59(31.0%) 94(76.4%)
  Unknown 29 18(9.5%) 11(9.0%)
PR status     <0.001
  Positive 133 128(67.4%) 5(4.1%)
  Negative 180 62(32.6%) 118(95.9%)
HER2/neu status     <0.001
  Positive 45 9(4.7%) 36(29.3%)
  Negative 246 170(89.5%) 76(61.8%)
  Unknown 22 11(5.8%) 11(8.9%)
Operation     0.014
  Conservation 175 117(61.6%) 58(47.2%)
  Mastectomy 138 73(38.4%) 65(52.8%)
Adjuvant chemotherapy     <0.001
  No 131 103(54.2%) 28(22.8%)
  Yes 182 87(45.8%) 95(77.2%)
Adjuvant Radiotherapy     0.129
  No 133 74(38.9%) 59(48.0%)
  Yes 180 116(61.1%) 64(52.0%)
Adjuvant hormonal therapy     
  No   3(1.6%)
  SERM   36(18.9%)
  AI   137(72.1%)
  Switch*   14(7.4%)
Distant metastasis   7(3.7%) 15(12.2%) 0.006
  1. Abbreviations: ER estrogen receptor, PR Progesterone receptor, SERM selective estrogen modulator, AI aromatase inhibitor.
  2. Switch*: Tamoxifen for 2–3 year, and then aromatase inhibitor to complete 5 year.